Onsdag 28 Oktober | 18:13:29 Europe / Stockholm
Est. tid*
2027-11-23 07:10 Kvartalsrapport 2027-Q3
2027-08-25 07:10 Kvartalsrapport 2027-Q2
2027-05-26 07:10 Kvartalsrapport 2027-Q1
2027-03-16 N/A Årsstämma
2027-02-24 07:05 Bokslutskommuniké 2026
2026-11-26 07:10 Kvartalsrapport 2026-Q3
2026-08-25 - Kvartalsrapport 2026-Q2
2026-05-27 - Kvartalsrapport 2026-Q1
2026-03-26 - X-dag ordinarie utdelning FLUO 0.00 DKK
2026-03-25 - Årsstämma
2026-02-25 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-03-28 - X-dag ordinarie utdelning FLUO 0.00 DKK
2025-03-27 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-29 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-19 - X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 - Årsstämma
2022-03-30 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 - Bokslutskommuniké 2020
2021-02-09 - Årsstämma
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-14 - Kvartalsrapport 2020-Q2
2020-05-27 - Kvartalsrapport 2020-Q1
2020-04-09 - X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-05-31 - Kvartalsrapport 2019-Q1
LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamt inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar av olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

FluoGuide receives approx. DKK 6.4 million through warrant exercise

2020-05-12 12:05:00
Thursday 7 May 2020 was the last day in the exercise period for FluoGuide A/S (“FluoGuide” or “the Company”) warrants of series TO 1. In total, 1,047,021 warrants of series TO 1 were exercised, corresponding to a subscription rate of approx. 97.4 percent. Prior to the warrant exercise period, the Company agreed on free-of-charge guarantee commitment. The Board of Directors of FluoGuide has today, based on the authorization from the Annual General Meeting, decided on a directed issue to the guarantors for the remaining approx. 2.6 percent. FluoGuide will thereby receive the full proceed of approx. DKK 6.4 million, before issue costs. Sedermera Fondkommission has acted as financial advisor and Markets & Corporate Law Nordic AB has acted as legal advisor.

”We are very pleased with our development and our shareholders’ interest in FluoGuide. The proceed from the warrants will contribute to transform FluoGuide from a pre-clinical organization now into a late clinical-phase company with a pipeline of indications and products during 2021” says Morten Albrechtsen, CEO  and continues: “As stated before, we believe FluoGuide has enormous potential and we look forward to deliver on this to shareholders and patients.”

Warrants of series TO 1 and directed issue
In total, 1,047,021 warrants of series TO 1 were exercised. In addition, and in accordance to what has previously been communicated, the Board of Directors has, based on the authorization from the Annual General Meeting 2020, decided to execute a directed issue of a total of 27,737 shares to Kurt Mähler (7,316 shares), Eastbridge Capital AB (6,807 shares), Peter Nilsson (4,538 shares), Stefan Lundgren (4,538 shares) and John Moll (4,538 shares). The share price in the directed issue corresponds to the exercise price in the warrant exercise, DKK 5.95 per share, providing the Company with a total of DKK 165,035.15 through the directed issue. No compensation has been given for the guarantee commitments left by the five parties.

To summarize, this means that a total of 1,074,758 new shares will be registered with Danish Business Authority (Danish “Erhvervsstyrelsen”). FluoGuide is therefore provided a total of approx. DKK 6.4 million before issue costs, which amount to approx. DKK 0.5 million.When the new shares have been registered with Danish Business Authority, the total number of shares in FluoGuide will amount to 10,530,026 shares and the share capital will amount to DKK 1,053,002.60.

Public disclosure of major changes in holdings
Due to the dilution, Wecotec ApS, which is CEO Morten Albrechtsen’s fully owned company that owns 1,487,394 shares in FluoGuide passes the 15% limit. Its shareholding goes from approx. 15.7 percent of the shares in the Company to owning approx. 14.1 percent.

Sedermera Fondkommission has acted as financial advisor in the warrant exercise and the directed issue. Markets & Corporate Law Nordic AB has acted as legal advisor.

 

FluoGuide A/S is obliged to publish this information in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on 12 May 2020.